Organigram Global Inc. reported first‑quarter fiscal 2026 revenue of $63.5 million, up 49% year‑over‑year, and net revenue of $97.3 million, a 46% increase. The company posted an EPS of $0.10, beating consensus estimates of a loss of $0.01 by $0.11, a 1100% beat.
Adjusted gross margin expanded to 38% from 33% in Q1 2025, driven by higher flower yields, cost efficiencies from the Motif integration, and a 208% jump in international sales. Adjusted EBITDA rose to $5.3 million, a 273% increase from $1.4 million, reflecting strong operating leverage and disciplined capital allocation.
International revenue surged 208% to $5.0 million, with Germany, Australia, and the U.S. hemp‑derived beverage markets contributing the largest upside. Domestic Canadian recreational sales remained robust, with non‑medical recreational revenue at $87.8 million and wholesale at $3.6 million, while medical revenue was $758,000.
Management reiterated full‑year guidance of net revenue above $300 million, higher adjusted gross margins than 2025, and positive free cash flow. The company also highlighted continued scaling of production capacity and advancement of its proprietary FAST technology, signaling confidence in sustaining growth.
Despite the strong results, Organigram noted a sequential decline in international flower volumes due to out‑of‑spec product, which reduced revenue by an estimated $3.5 million. The company remains awaiting EU‑GMP certification for its Moncton facility and faces potential U.S. federal hemp law changes that could require restructuring of hemp‑derived THC activities by November 2026.
CEO James Yamanaka said the quarter demonstrated the strength of Organigram’s core business and the effectiveness of its innovation pipeline, while CFO Greg Guyatt highlighted operational efficiencies from Motif integration and projected continued margin expansion throughout fiscal 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.